Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga-DWJ155 in Advanced Breast Cancer and Advanced NSCLC
NCT07117214Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Primary completion
- Jan 2029
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of [68Ga]Ga-DWJ155 in breast cancer and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Novartis. Primary endpoints: Standard Uptake Value mean and max at 240 minutes and Standard Uptake Value ratio at 240 minutes. Started Jun 2026; status: recruiting.
02
Drugs
[68Ga]Ga-DWJ155
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07117214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117214.